United Nations, Department of Economics and Social Affairs, Population Division. World population prospects 2019. New York (NY): United Nations;2019.
Statistics Korea. Elderly statistics 2018 [Internet]. Daejeon: Statistics Korea;2018 [cited 2018 Sep 27].
McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004; 56: 163-84.
Cheong SJ, Yoon JL, Choi SH, Kim MY, Cho JJ, Ju YS. The Effect of polypharmacy on mortality in the elderly. Korean J Fam Pract 2016; 6: 643-50.
Fried TR, O'Leary J, Towle V, Goldstein MK, Trentalange M, Martin DK. Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review. J Am Geriatr Soc 2014; 62: 2261-72.
Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother 2007; 5: 345-51.
Herr M, Robine JM, Pinot J, Arvieu JJ, Ankri J. Polypharmacy and frailty:prevalence, relationship, and impact on mortality in a French sample of 2350 old people. Pharmacoepidemiol Drug Saf 2015; 24: 637-46.
Payne RA, Abel GA, Avery AJ, Mercer SW, Roland MO. Is polypharmacy always hazardous? A retrospective cohort analysis using linked electronic health records from primary and secondary care. Br J Clin Pharmacol 2014;77: 1073-82.
Lees J, Chan A. Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol 2011; 12: 1249-57.
Kim HA, Shin JY, Kim MH, Park BJ. Prevalence and predictors of polypharmacy among Korean elderly. PLoS One 2014; 9: e98043.
World Health Organization. A glossary of terms for community health care and services for older persons. Geneva: World Health Organization; 2004.
Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Waite L, Seibel MJ, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol 2012; 65: 989-95.
Hovstadius B, Hovstadius K, Astrand B, Petersson G. Increasing polypharmacy - an individual-based study of the Swedish population 2005-2008. BMC Clin Pharmacol 2010; 10: 16.
Moriarty F, Hardy C, Bennett K, Smith SM, Fahey T. Trends and interaction of polypharmacy and potentially inappropriate prescribing in primary care over 15 years in Ireland: a repeated cross-sectional study. BMJ Open 2015; 5:e008656.
Nobili A, Franchi C, Pasina L, Tettamanti M, Baviera M, Monesi L, et al. Drug utilization and polypharmacy in an Italian elderly population: the EPIFARM-elderly project. Pharmacoepidemiol Drug Saf 2011; 20: 488-96.
van den Bussche H, Koller D, Kolonko T, Hansen H, Wegscheider K, Glaeske G, et al. Which chronic diseases and disease combinations are specific to multimorbidity in the elderly? Results of a claims data based cross-sectional study in Germany. BMC Public Health 2011; 11: 101.
Slabaugh SL, Maio V, Templin M, Abouzaid S. Prevalence and risk of polypharmacy among the elderly in an outpatient setting: a retrospective cohort study in the Emilia-Romagna region, Italy. Drugs Aging 2010; 27: 1019-28.
Kim AR. Assessment of polypharmacy and potentially inappropriate medication in elderly outpatients [dissertation]. Seoul: Ewha Womans Univ.;2015. Korean.
Park BJ, Jung JH, Park KD, Soe SW, Kim SW. Study on diagnosis accuracy for health insurance claims data in Korea, report to Health Insurance Review and Assessment Services. Seoul: Medical School of Seoul National University; 2003. p. 17-29.